Shafaat Rabbani

Dr. Shafaat Rabbani

Department of Medicine, Human Genetics, Physiology and Oncology, McGill University Health Centre, Montreal, QC, Canada
orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2018 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
NMNiaz Mahmood
Niaz Mahmood
CMCatalin Mihalcioiu
Catalin Mihalcioiu
Shafaat RabbaniShafaat Rabbani
Shafaat Rabbani
The plasminogen activator (PA) system is an extracellular proteolytic enzyme system associated with various physiological and pathophysiological processes. A large body of evidence support that among the various components of the PA system, urokinase-type plasminogen activator (uPA), its receptor (uPAR), and plasminogen activator inhibitor-1 and -2 (PAI-1 and PAI-2) play a major role in tumor progression and metastasis. The binding of uPA with uPAR is instrumental for the activation of plasminogen to plasmin, which in turn initiates a series of proteolytic cascade to degrade the components of the extracellular matrix, and thereby, cause tumor cell migration from the primary site of origin to a distant secondary organ. The components of the PA system show altered expression patterns in several common malignancies, which have identified them as ideal diagnostic, prognostic, and therapeutic targets to reduce cancer-associated morbidity and mortality. This review summarizes the various components of the PA system and focuses on the role of uPA–uPAR in different biological processes especially in the context of malignancy. We also discuss the current state of knowledge of uPA–uPAR-targeted diagnostic and therapeutic strategies for various malignancies.

12 February 2009 in Cancer Research
Verified
Journal Article
Open access
PDF file
LDLaetitia Devy
Laetitia Devy
LHLili Huang
Lili Huang
LNLaurent Naa
Laurent Naa
NYNiranjan Yanamandra
Niranjan Yanamandra
HPHenk Pieters
Henk Pieters
DDDaniel T. Dransfield
Daniel T. Dransfield
Inhibition of specific matrix metalloproteinases (MMP) is an attractive noncytotoxic approach to cancer therapy. MMP-14, a membrane-bound zinc endopeptidase, has been proposed to play a central role in tumor growth, invasion, and neovascularization. Besides cleaving matrix proteins, MMP-14 activates proMMP-2 leading to an amplification of pericellular proteolytic activity. To examine the contribution of MMP-14 to tumor growth and angiogenesis, we used DX-2400, a highly selective fully human MMP-14 inhibitory antibody discovered using phage display technology. DX-2400 blocked proMMP-2 processing on tumor and endothelial cells, inhibited angiogenesis, and slowed tumor progression and formation of metastatic lesions. The combination of potency, selectivity, and robust in vivo activity shows the potential of a selective MMP-14 inhibitor for the treatment of solid tumors. [Cancer Res 2009;69(4):1517–26]

4 August 2004 in Cancer
Verified
Journal Article
Closed access
GCGaoping Chen
Gaoping Chen
NSNicholas Shukeir
Nicholas Shukeir
APAnil Potti
Anil Potti
KSKanishka Sircar
Kanishka Sircar
AAArmen Aprikian
Armen Aprikian
Shafaat RabbaniShafaat Rabbani
Shafaat Rabbani

5 July 2006 in Cancer
Verified
Journal Article
Open access
PDF file
GCGaoping Chen
Gaoping Chen
KSKanishka Sircar
Kanishka Sircar
AAArmen Aprikian
Armen Aprikian
APAnil Potti
Anil Potti
DGDavid Goltzman
David Goltzman
Shafaat RabbaniShafaat Rabbani
Shafaat Rabbani
BACKGROUND: Late‐stage prostate cancer patients are refractory to hormone therapy and exhibit a high propensity to develop skeletal metastasis. In this regard, the role of a novel cytokine system belonging to the tumor necrosis factor (TNF) family that is critical for osteoclastic osteolysis and that consists of receptor activator of NF‐κB ligand (RANKL), its receptor (RANK), and decoy receptor osteoprotegerin (OPG) is of potential interest.METHODS: Reverse‐transcriptase polymerase chain reaction (RT‐PCR) and immunohistochemical analysis was used to examine the expression of RANKL, RANK, and OPG in human prostate cancer cell lines and in 89 archival samples of primary and metastatic (lymph nodes, skeleton) prostate cancer patients. Expression of these proteins was correlated with clinicopathogic parameters of the prostate cancer.RESULTS: Expression of RANKL/RANK/OPG was low in normal but markedly higher in prostate cancer cell lines. Analysis of surgical biopsy specimens showed the expression of RANKL (31%), RANK (38%), and OPG (19%) in primary carcinoma. The expression frequency was significantly higher (RANKL [44%], RANK [49%], and OPG [73%]) in metastatic prostate cancer. OPG (83%) production was more common in skeletal as compared with lymph node metastases (46%), whereas the expression of RANKL expression was less discordant in bone (47%) and lymph node metastases (36%). The increased expression of RANKL/RANK/OPG observed correlated with Gleason score, TNM stage, androgen status, and serum prostate‐specific antigen (PSA) levels in the prostate cancer patients.CONCLUSIONS: Expression of RANKL/RANK/OPG correlates with more aggressive, advanced, metastatic prostate carcinoma to suggest their role as diagnostic, prognostic, and therapeutic targets for prostate cancer. Cancer 2006. © 2006 American Cancer Society.

1 September 2006 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PKParisa Khalili
Parisa Khalili
AAAni Arakelian
Ani Arakelian
GCGaoping Chen
Gaoping Chen
MPMarian L. Plunkett
Marian L. Plunkett
IBIvy Beck
Ivy Beck
Shafaat RabbaniShafaat Rabbani
Shafaat Rabbani
Purpose: Integrins are expressed by numerous tumor types including breast cancer, in which they play a crucial role in tumor growth and metastasis. In this study, we evaluated the ability of ATN-161 (Ac-PHSCN-NH2), a 5-mer capped peptide derived from the synergy region of fibronectin that binds to α5β1 and αvβ3 in vitro, to block breast cancer growth and metastasis. Experimental design: MDA-MB-231 human breast cancer cells were inoculated s.c. in the right flank, or cells transfected with green fluorescent protein (MDA-MB-231-GFP) were inoculated into the left ventricle of female BALB/c nu/nu mice, resulting in the development of skeletal metastasis. Animals were treated with vehicle alone or by i.v. infusion with ATN-161 (0.05–1 mg/kg thrice a week) for 10 weeks. Tumor volume was determined at weekly intervals and tumor metastasis was evaluated by X-ray, microcomputed tomography, and histology. Tumors were harvested for histologic evaluation. Result: Treatment with ATN-161 caused a significant dose-dependent decrease in tumor volume and either completely blocked or caused a marked decrease in the incidence and number of skeletal as well as soft tissue metastases. This was confirmed histologically as well as radiographically using X-ray and microcomputed tomography. Treatment with ATN-161 resulted in a significant decrease in the expression of phosphorylated mitogen-activated protein kinase, microvessel density, and cell proliferation in tumors grown in vivo. Conclusion: These studies show that ATN-161 can block breast cancer growth and metastasis, and provides a rationale for the clinical development of ATN-161 for the treatment of breast cancer. [Mol Cancer Ther 2006;5(9):2271–80]

1 September 2004 in Biochemical Pharmacology
Verified
Journal Article
Closed access
MSMoshe Szyf
Moshe Szyf
PPPouya Pakneshan
Pouya Pakneshan
Shafaat RabbaniShafaat Rabbani
Shafaat Rabbani